These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26423040)

  • 21. Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists.
    Ando M; Sekino E; Haga Y; Moriya M; Ito M; Ito J; Iwaasa H; Ishihara A; Kanatani A; Ohtake N
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5186-90. PubMed ID: 19632840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
    J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.
    Wu CH; Hung MS; Song JS; Yeh TK; Chou MC; Chu CM; Jan JJ; Hsieh MT; Tseng SL; Chang CP; Hsieh WP; Lin Y; Yeh YN; Chung WL; Kuo CW; Lin CY; Shy HS; Chao YS; Shia KS
    J Med Chem; 2009 Jul; 52(14):4496-510. PubMed ID: 19530697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanism of agonism and inverse agonism in ghrelin receptor.
    Qin J; Cai Y; Xu Z; Ming Q; Ji SY; Wu C; Zhang H; Mao C; Shen DD; Hirata K; Ma Y; Yan W; Zhang Y; Shao Z
    Nat Commun; 2022 Jan; 13(1):300. PubMed ID: 35027551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-terminus of a hexapeptidic ghrelin receptor inverse agonist can switch peptide behavior from inverse agonism to agonism.
    Els-Heindl S; Bellmann-Sickert K; Beck-Sickinger AG
    Biopolymers; 2016 Jan; 106(1):101-8. PubMed ID: 26566778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Side Chain Orientation of Tryptophan Analogues Determines Agonism and Inverse Agonism in Short Ghrelin Peptides.
    Nicke L; Müller R; Geyer A; Els-Heindl S
    ChemMedChem; 2019 Nov; 14(21):1849-1855. PubMed ID: 31442005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of Nonpeptidic Inverse Agonists of the Ghrelin Receptor (GHSR) Based on the 1,2,4-Triazole Scaffold.
    Haj Salah KB; Maingot M; Blayo AL; M'Kadmi C; Damian M; Mary S; Cantel S; Neasta J; Oiry C; Péraldi-Roux S; Fernandez G; Romero GG; Perello M; Marie J; Banères JL; Fehrentz JA; Denoyelle S
    J Med Chem; 2020 Oct; 63(19):10796-10815. PubMed ID: 32882134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
    Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
    Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational Design, Synthesis, and Pharmacological Characterization of Novel Ghrelin Receptor Inverse Agonists as Potential Treatment against Obesity-Related Metabolic Diseases.
    Daina A; Giuliano C; Pietra C; Wang J; Chi Y; Zou Z; Li F; Yan Z; Zhou Y; Guainazzi A; Garcia Rubio S; Zoete V
    J Med Chem; 2018 Dec; 61(24):11039-11060. PubMed ID: 30265805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor.
    McClure KF; Jackson M; Cameron KO; Kung DW; Perry DA; Orr ST; Zhang Y; Kohrt J; Tu M; Gao H; Fernando D; Jones R; Erasga N; Wang G; Polivkova J; Jiao W; Swartz R; Ueno H; Bhattacharya SK; Stock IA; Varma S; Bagdasarian V; Perez S; Kelly-Sullivan D; Wang R; Kong J; Cornelius P; Michael L; Lee E; Janssen A; Steyn SJ; Lapham K; Goosen T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5410-4. PubMed ID: 23953189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ghrelin receptor modulators and their therapeutic potential.
    Costantino L; Barlocco D
    Future Med Chem; 2009 Apr; 1(1):157-77. PubMed ID: 21426074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist.
    Hung MS; Chang CP; Li TC; Yeh TK; Song JS; Lin Y; Wu CH; Kuo PC; Amancha PK; Wong YC; Hsiao WC; Chao YS; Shia KS
    ChemMedChem; 2010 Sep; 5(9):1439-43. PubMed ID: 20652930
    [No Abstract]   [Full Text] [Related]  

  • 33. Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
    Alig L; Alsenz J; Andjelkovic M; Bendels S; Bénardeau A; Bleicher K; Bourson A; David-Pierson P; Guba W; Hildbrand S; Kube D; Lübbers T; Mayweg AV; Narquizian R; Neidhart W; Nettekoven M; Plancher JM; Rocha C; Rogers-Evans M; Röver S; Schneider G; Taylor S; Waldmeier P
    J Med Chem; 2008 Apr; 51(7):2115-27. PubMed ID: 18335976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of 1,2,3-triazole-based fibroblast growth factor receptor modulators.
    Sakai H; Inoue H; Toba T; Murata K; Narii N; Shimmyo Y; Igawa Y; Matsumoto T; Takemoto N
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2332-2337. PubMed ID: 31255484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An aromatic region to induce a switch between agonism and inverse agonism at the ghrelin receptor.
    Els S; Schild E; Petersen PS; Kilian TM; Mokrosinski J; Frimurer TM; Chollet C; Schwartz TW; Holst B; Beck-Sickinger AG
    J Med Chem; 2012 Sep; 55(17):7437-49. PubMed ID: 22920150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ghrelin receptor controls obesity by fat burning.
    Sun Y
    Oncotarget; 2015 Mar; 6(9):6470-1. PubMed ID: 25823665
    [No Abstract]   [Full Text] [Related]  

  • 37. Recent developments in ghrelin receptor ligands.
    Moulin A; Ryan J; Martinez J; Fehrentz JA
    ChemMedChem; 2007 Sep; 2(9):1242-59. PubMed ID: 17520591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone secretagogue receptor antagonists as anti-obesity therapies? Still an open question.
    Zhao H; Liu G
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):509-15. PubMed ID: 16889233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Hagmann WK
    Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homogeneous time-resolved fluorescence-based assay to screen for ligands targeting the growth hormone secretagogue receptor type 1a.
    Leyris JP; Roux T; Trinquet E; Verdié P; Fehrentz JA; Oueslati N; Douzon S; Bourrier E; Lamarque L; Gagne D; Galleyrand JC; M'kadmi C; Martinez J; Mary S; Banères JL; Marie J
    Anal Biochem; 2011 Jan; 408(2):253-62. PubMed ID: 20937574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.